Bifogade filer
Kurs
+8,87%
Kalender
Tid* | ||
2025-02-27 | 08:00 | Bokslutskommuniké 2024 |
2024-12-05 | - | Split POLAR 300:1 |
2024-11-29 | - | Kvartalsrapport 2024-Q3 |
2024-11-19 | - | Extra Bolagsstämma 2024 |
2024-08-30 | - | Kvartalsrapport 2024-Q2 |
2024-05-31 | - | Kvartalsrapport 2024-Q1 |
2024-05-29 | - | X-dag ordinarie utdelning POLAR 0.00 SEK |
2024-05-28 | - | Årsstämma |
2024-02-23 | - | Bokslutskommuniké 2023 |
2023-11-24 | - | Kvartalsrapport 2023-Q3 |
2023-09-08 | - | Extra Bolagsstämma 2023 |
2023-08-25 | - | Kvartalsrapport 2023-Q2 |
2023-05-26 | - | Kvartalsrapport 2023-Q1 |
2023-05-17 | - | Årsstämma |
2023-05-05 | - | X-dag ordinarie utdelning POLAR 0.00 SEK |
2023-03-13 | - | Extra Bolagsstämma 2022 |
2023-02-24 | - | Bokslutskommuniké 2022 |
2022-11-25 | - | Kvartalsrapport 2022-Q3 |
2022-08-26 | - | Kvartalsrapport 2022-Q2 |
2022-05-27 | - | Kvartalsrapport 2022-Q1 |
2022-05-06 | - | X-dag ordinarie utdelning POLAR 0.00 SEK |
2022-05-05 | - | Årsstämma |
2022-02-25 | - | Bokslutskommuniké 2021 |
2021-11-26 | - | Kvartalsrapport 2021-Q3 |
2021-08-27 | - | Kvartalsrapport 2021-Q2 |
2021-05-28 | - | Kvartalsrapport 2021-Q1 |
2021-05-06 | - | X-dag ordinarie utdelning POLAR 0.00 SEK |
2021-05-05 | - | Årsstämma |
2021-02-26 | - | Bokslutskommuniké 2020 |
2020-11-27 | - | Kvartalsrapport 2020-Q3 |
2020-08-28 | - | Kvartalsrapport 2020-Q2 |
2020-07-01 | - | X-dag ordinarie utdelning POLAR 0.00 SEK |
2020-06-30 | - | Årsstämma |
2020-05-29 | - | Kvartalsrapport 2020-Q1 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2020-02-14 | - | Extra Bolagsstämma 2020 |
2019-10-23 | - | Kvartalsrapport 2019-Q3 |
2019-07-24 | - | Kvartalsrapport 2019-Q2 |
2019-05-07 | - | Split POLAR 16:1 |
2019-04-26 | - | Kvartalsrapport 2019-Q1 |
2019-03-19 | - | Årsstämma |
2019-02-04 | - | X-dag ordinarie utdelning POLAR 0.00 SEK |
2019-02-01 | - | Bokslutskommuniké 2018 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
Mangold Insight has initiated coverage of PolarCool AB (publ.) with a target price of SEK 10.0 per share and has published an initial analysis today.
Mangold identifies significant growth opportunities for the company due to its first-mover advantage in a large, undeveloped market. With a fully developed and scientifically validated product, the company is well-positioned to capitalize on an anticipated FDA approval in the United States. Furthermore, Mangold highlights strong demand in Canada and the potential for significant sales growth through larger agreements and continued scientific validation.
Link to the analysis: Mangold Insight - PolarCool
For more information
Erik Andersson - CEO PolarCool AB (publ.)
+46 - 73 860 57 00
E-mail: erik.andersson@polarcool.se
About PolarCool AB (publ.)
PolarCool AB (publ.) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ.) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.